Nucleotide analogs

Information

  • Patent Grant
  • 7476734
  • Patent Number
    7,476,734
  • Date Filed
    Tuesday, December 6, 2005
    20 years ago
  • Date Issued
    Tuesday, January 13, 2009
    17 years ago
Abstract
The invention provides nucleotide analogs for use in sequencing nucleic acid molecules.
Description
FIELD OF THE INVENTION

The invention relates to nucleotide analogs and methods for sequencing a nucleic acid using nucleotide analogs.


BACKGROUND

There have been proposals to develop new sequencing technologies based on single-molecule measurements. For example, sequencing strategies have been proposed that are based upon observing the interaction of particular proteins with DNA or by using ultra high resolution scanned probe microscopy. See, e.g., Rigler, et al., J. Biotechnol., 86(3):161 (2001); Goodwin, P. M., et al., Nucleosides & Nucleotides, 16(5-6):543-550 (1997); Howorka, S., et al., Nature Biotechnol., 19(7):636-639 (2001); Meller, A., et al., Proc. Nat'l. Acad. Sci., 97(3):1079-1084 (2000); Driscoll, R. J., et al., Nature, 346(6281):294-296 (1990).


Recently, a sequencing-by-synthesis methodology has been proposed that resulted in sequence determination, but not with consecutive base incorporation. See, Braslavsky, et al., Proc. Nat'l Acad. Sci., 100: 3960-3964 (2003). An impediment to base-over-base sequencing has been the use of bulky fluorophores that can sterically hinder sequential base incorporation. Even when the label is cleaved, some fluorescently-labeled nucleotides sterically hinder subsequent base incorporation due to the residue of the linker left behind after cleavage.


A need therefore exists for nucleotide analogs having reduced steric hindrance, thereby allowing the polymerase to produce greater read-length from each template.


SUMMARY OF THE INVENTION

The present invention provides nucleotide analogs and methods of using nucleotide analogs in sequencing. A nucleotide analog of the invention features a cleavable linker between the base portion of the nucleotide and the label.


In general, nucleotide analogs comprise an inhibitory molecule that reduces the likelihood of subsequent incorporation of a second nucleotide or nucleotide analog to a primer during sequencing-by-synthesis. Preferably, the inhibitory molecule is removable so that additional incorporation of nucleotides or nucleotide analogs may be accomplished. According to the invention, the inhibitory molecule can be attached anywhere on the nucleotide analogs so long as it inhibits the subsequent addition of additional nucleotides or nucleotide analogs. A preferred inhibitory molecule is a dideoxynucleotide, however any appropriate inhibitory can be used according to the invention, such as, for example, a label. In general, an inhibitory molecule includes any molecule that provides sterically hinders the subsequent incorporation of additional nucleotides or nucleotide analogs during sequencing-by-synthesis. Functionally, in some embodiments, an inhibitory molecule can block the active site of the polymerase thereby inhibiting or limiting the incorporation of additional nucleotides or nucleotide analogs. Subsequent addition of nucleotides and nucleotide analogs can be accomplished after removing the inhibitory molecule.


In a preferred embodiment, a nucleotide analog of the invention is a nucleotide triphosphate comprising an optically-detectable label attached to the nitrogenous base portion of the nucleotide via a cleavable linker. Examples of preferred linkers are provided below.


Cleavage may be accomplished via any appropriate method and/or combination of methods. Specific examples are provided below. For example, a cleavage site may be chemically cleavable, photolytically cleavable, or mechanically cleavable (i.e., by shaking). Chemical cleaving can be accomplished by exposing the linker to one or more pH level. The cleavable bond can be cleaved upon exposure to a pH of from about 11.3 to about 12.3, more particularly upon exposure to a pH of about 11.8. A preferred cleavage site is a carboxyl nitrogen bond, which can be positioned in the linker in order to effect the purposes of the invention.


Any detectable label can be used in practice of the invention. Optically-detectable labels, and particularly fluorescent labels, are highly preferred. The base is selected from the group consisting of a purine, a pyrimidine and derivatives. Analogs of the invention may be further modified by inclusion of a blocking group at the 3′ hydroxyl position on the sugar moiety of the nucleotide. For example, a preferred analog comprises a phosphate group in place of the hydroxyl group in the 3′ position of the nucleotide sugar.


In general, methods of using nucleotide analogs of the invention comprise exposing a target nucleic acid/primer duplex to one or more nucleotide analogs and a polymerase under conditions suitable to extend the primer in a template dependent manner. Any appropriate polymerase can be used according to the invention. For example, in one embodiment, a Klenow fragment with reduced exonuclease activity is used to extend the primer in a template-dependent manner. Generally, the primer is, or is made to be, sufficiently complementary to at least a portion of the target nucleic acid to hybridize to the target nucleic acid and allow template-dependent nucleotide polymerization. The primer is extended by one or more bases.


In one embodiment, a labeled nucleotide analog having a linker with a cleavable bond with a carboxyl nitrogen bond is incorporated into a primer portion of a nucleic acid duplex comprising a template to be hybridized to the primer. The incorporated labeled nucleotide is identified and the cleavable bond is cleaved. The incorporating, identifying, and cleaving steps are repeated at least one time and a sequence of the target nucleic acid/primer duplex is determined based upon the order of the incorporation of the labeled nucleotides. The cleaving step can include exposing the cleavable bond to a pH of from about 11.3 to about 12.3, preferably, exposing the cleavable bond to a pH of about 11.8. Optionally, the cleaved bond is capped (for example, with an alkylating agent), rendering it unreactive. Common alkylating agents, such as iodoacetamide, are used to cap the cleaved bond.


In single molecule sequencing, the template nucleic acid molecule/primer duplex is immobilized on a surface such that nucleotides (or nucleotide analogs) added to the immobilized primer are individually optically resolvable. Either the primer, template and/or nucleotide analogs can be detectably labeled such that the position of the duplex is individually optically resolvable. The primer can be attached to the solid support, thereby immobilizing the hybridized template nucleic acid molecule, or the template can be attached to the solid support thereby immobilizing the hybridized primer. The primer and template can be hybridized to each other prior to or after attachment of either the template or the primer to the solid support. The detectable label preferably is optically-detectable, and most preferably is a fluorescent label. Examples of appropriate fluorescent labels include cyanine, rhodamine, fluorescien, coumarin, BODIPY, alexa, conjugated multi-dyes, or any combination of these.


Where an optional phosphate group is present in place of the hydroxyl in the 3′ position of the nucleotide sugar, the optional phosphate moiety is removed, preferably enzymatically, after incorporation in order to allow subsequent incorporations. The incorporated nucleotide analog can be detected before, during, or after removing the optional phosphate group.


The primer extension process can be repeated to identify additional nucleotide analogs in the template. The sequence of the template is determined by compiling the detected nucleotides, thereby determining the complimentary sequence of the target nucleic acid molecule.


In general, methods for facilitating the incorporation of a nucleotide analog in a primer include exposing a target nucleic acid/primer duplex to one or more nucleotide analogs of the present invention and a polymerase under conditions suitable to extend the primer in a template dependent manner. Generally, the primer is sufficiently complementary to at least a portion of the target nucleic acid to hybridize to the target nucleic acid and allow template-dependent nucleotide polymerization.


While the invention is exemplified herein with fluorescent labels, the invention is not so limited and can be practiced using nucleotides labeled with any detectable label, including chemiluminescent labels, luminescent labels, phosphorescent labels, fluorescence polarization labels, and charge labels.


A detailed description of the certain embodiments of the invention is provided below. Other embodiments of the invention are apparent upon review of the detailed description that follows.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 shows exemplary chemical structures of nucleotide analogs of the present invention having a linker between the base B and the label.



FIG. 2 shows exemplary chemical structures of nucleotide analogs of the present invention having a linker between the base and the label that undergo cleavage of the linker between the base and the label.





DETAILED DESCRIPTION OF THE INVENTION

The invention relates to nucleotide analogs that, when used in sequencing reactions, allow extended base-over-base incorporation into a primer in a template-dependent sequencing reaction. Analogs of the invention are useful in sequencing-by-synthesis reactions in which consecutive based are added to a primer in a template-dependent manner.


Nucleotide Analogs


Preferred nucleotide analogs of the invention have the generalized structure (also as shown in FIG. 1):




embedded image


The base B can be, for example, adenine, cytosine, guanine, thymine, uracil, or hypoxanthine. The base B can also be, for example, naturally-occurring and synthetic derivatives of the preceding group, including pyrazolo[3,4-d]pyrimidines, 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo (e.g., 8-bromo), 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, deazaguanine, 7-deazaguanine, 3-deazaguanine, deazaadenine, 7-deazaadenine, 3-deazaadenine, pyrazolo[3,4-d]pyrimidine, imidazo[1,5-a]1,3,5 triazinones, 9-deazapurines, imidazo[4,5-d]pyrazines, thiazolo[4,5-d]pyrimidines, pyrazin-2-ones, 1,2,4-triazine, pyridazine; and 1,3,5 triazine. Bases useful according to the invention permit a nucleotide that includes that base to be incorporated into a polynucleotide chain by a polymerase and will form base pairs with a base on an antiparallel nucleic acid strand. The term base pair encompasses not only the standard AT, AU or GC base pairs, but also base pairs formed between nucleotides and/or nucleotide analogs comprising non-standard or modified bases, wherein the arrangement of hydrogen bond donors and hydrogen bond acceptors permits hydrogen bonding between a non-standard base and a standard base or between two complementary non-standard base structures. One example of such non-standard base pairing is the base pairing between the nucleotide analog inosine and adenine, cytosine or uracil, where the two hydrogen bonds are formed.


Other preferred nucleotide analogs of the invention have the generalized structure:




embedded image


Label for use with the invention preferably is a detectable label. In one embodiment, the label is an optically-detectable label such as a fluorescent label. The label can be selected from detectable labels including cyanine, rhodamine, fluorescien, coumarin, BODIPY, alexa, conjugated multi-dyes, or any combination of these. However, any appropriate detectable label can be used according to the invention, and are known to those skilled in the art.


Nucleic Acid Sequencing


The invention also includes methods for nucleic acid sequence determination using the nucleotide analogs described herein. The nucleotide analogs of the present invention are particularly suitable for use in single molecule sequencing techniques. In general, methods for nucleic acid sequence determination comprise exposing a target nucleic acid (also referred to herein as template nucleic acid or template) to a primer that is complimentary to at least a portion of the target nucleic acid, under conditions suitable for hybridizing the primer to the target nucleic acid, forming a template/primer duplex.


Target nucleic acids include deoxyribonucleic acid (DNA) and/or ribonucleic acid (RNA). Target nucleic acid molecules can be obtained from any cellular material, obtained from an animal, plant, bacterium, virus, fungus, or any other cellular organism. Target nucleic acids may be obtained directly from an organism or from a biological sample obtained from an organism, e.g., from blood, urine, cerebrospinal fluid, seminal fluid, saliva, sputum, stool and tissue. Any tissue or body fluid specimen may be used as a source for nucleic acid for use in the invention. Nucleic acid molecules may also be isolated from cultured cells, such as a primary cell culture or a cell line. The cells from which target nucleic acids are obtained can be infected with a virus or other intracellular pathogen.


A sample can also be total RNA extracted from a biological specimen, a cDNA library, or genomic DNA. Nucleic acid typically is fragmented to produce suitable fragments for analysis. In one embodiment, nucleic acid from a biological sample is fragmented by sonication. Test samples can be obtained as described in U.S. Patent Application 2002/0190663 A1, published Oct. 9, 2003, the teachings of which are incorporated herein in their entirety. Generally, nucleic acid can be extracted from a biological sample by a variety of techniques such as those described by Maniatis, et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, N.Y., pp. 280-281 (1982). Generally, target nucleic acid molecules can be from about 5 bases to about 20 kb. Nucleic acid molecules may be single-stranded, double-stranded, or double-stranded with single-stranded regions (for example, stem- and loop-structures).


Any polymerase and/or polymerizing enzyme may be employed. A preferred polymerase is Klenow with reduced exonuclease activity. Nucleic acid polymerases generally useful in the invention include DNA polymerases, RNA polymerases, reverse transcriptases, and mutant or altered forms of any of the foregoing. DNA polymerases and their properties are described in detail in, among other places, DNA Replication 2nd edition, Komberg and Baker, W. H. Freeman, New York, N.Y. (1991). Known conventional DNA polymerases useful in the invention include, but are not limited to, Pyrococcus furiosus (Pfu) DNA polymerase (Lundberg et al., 1991, Gene, 108: 1, Stratagene), Pyrococcus woesei (Pwo) DNA polymerase (Hinnisdaels et al., 1996, Biotechniques, 20:186-8, Boehringer Mannheim), Thermus thermophilus (Tth) DNA polymerase (Myers and Gelfand 1991, Biochemistry 30:7661), Bacillus stearothermophilus DNA polymerase (Stenesh and McGowan, 1977, Biochim Biophys Acta 475:32), Thermococcus litoralis (Tli) DNA polymerase (also referred to as Vent™ DNA polymerase, Cariello et al., 1991, Polynucleotides Res, 19: 4193, New England Biolabs), 9° Nm™ DNA polymerase (New England Biolabs), Stoffel fragment, ThermoSequenase® (Amersham Pharmacia Biotech UK), Therminator™ (New England Biolabs), Thermotoga maritima (Tma) DNA polymerase (Diaz and Sabino, 1998 Braz J. Med. Res, 31:1239), Thermus aquaticus (Taq) DNA polymerase (Chien et al., 1976, J. Bacteoriol, 127: 1550), DNA polymerase, Pyrococcus kodakaraensis KOD DNA polymerase (Takagi et al., 1997, Appl. Environ. Microbiol. 63:4504), JDF-3 DNA polymerase (from thermococcus sp. JDF-3, Patent application WO 0132887), Pyrococcus GB-D (PGB-D) DNA polymerase (also referred as Deep Vent™ DNA polymerase, Juncosa-Ginesta et al., 1994, Biotechniques, 16:820, New England Biolabs), UlTma DNA polymerase (from thermophile Thermotoga maritima; Diaz and Sabino, 1998 Braz J. Med. Res, 31:1239; PE Applied Biosystems), Tgo DNA polymerase (from thermococcus gorgonarius, Roche Molecular Biochemicals), E. coli DNA polymerase I (Lecomte and Doubleday, 1983, Polynucleotides Res. 11:7505), T7 DNA polymerase (Nordstrom et al., 1981, J. Biol. Chem. 256:3112), and archaeal DP1I/DP2 DNA polymerase II (Cann et al., 1998, Proc Natl Acad. Sci. USA 95:14250→5).


Other DNA polymerases include, but are not limited to, ThermoSequenase®, 9° Nm™, Therminator™, Taq, Tne, Tma, Pfu, Tfl, Tth, Tli, Stoffel fragment, Vent™ and Deep Vent™ DNA polymerase, KOD DNA polymerase, Tgo, JDF-3, and mutants, variants and derivatives thereof. Reverse transcriptases useful in the invention include, but are not limited to, reverse transcriptases from HIV, HTLV-1, HTLV-II, FeLV, FIV, SIV, AMV, MMTV, MoMuLV and other retroviruses (see Levin, Cell 88:5-8 (1997); Verma, Biochim Biophys Acta. 473:1-38 (1977); Wu et al., CRC Crit. Rev Biochem. 3:289-347 (1975)).


Unincorporated nucleotide analog molecules are removed prior to or after detecting. Unincorporated nucleotide analog molecules can be removed by washing.


The template/primer duplex is then treated such that the label is removed or the linker is cleaved, partially removed and/or degraded. The steps of exposing template/primer duplex to one or more nucleotide analogs and polymerase, detecting incorporated nucleotides, and then treating to (1) remove and/or degrade the label, (2) remove and/or degrade the label and at least a portion of the linker or (3) cleave the linker can be repeated, thereby identifying additional bases in the template nucleic acid, the identified bases can be compiled, thereby determining the sequence of the target nucleic acid. In some embodiments, the remaining linker and label are not removed, for example, in the last round of primer extension.


The above-described methods for sequencing a nucleic acid template can further include a step of capping the cleavable bond for example, after the bond has been cleaved. The methods for sequencing a nucleic acid template may employ a detectable label selected from, for example, cyanine, rhodamine, fluorescien, coumarin, BODIPY, alexa, conjugated multi-dyes or any combination of these. The template can be individually optically resolvable and is optionally attached to a surface.


In one embodiment, the cleavable linker has a carboxyl nitrogen bond that is chemically cleavable and the linker is cleaved by exposing the extended primer to a pH of about 11.8, thereby causing the removal of the label and at least a portion of the linker from the incorporated nucleotide analog.


Scheme 1

In one embodiment, according to Scheme 1, the linker features a cleavable bond, for example, a carboxyl nitrogen bond, which is located between about 10 atoms and about 1 atom from the uridine base. The carboxyl nitrogen bond can be cleaved upon exposure to a pH of between about 11.3 and about 12.3, more particularly a pH of about 11.8.


Linkers can be cleaved or degraded under acidic, basic, oxidative, or reductive conditions. In a preferred embodiment, chemical cleavage is accomplished using a reducing agent, such as TCEP (tris(2-carboxyethyl) phosphine hydrochloride), β-mercaptoethanol, or DTT (dithiothreitol). In one embodiment, the linker is cleaved upon exposure to a solution having a pH ranging from about 11.3 to about 12.3. Optionally, the remaining portion of the linker is treated with an agent that renders it chemically unreactive.


Referring now to FIG. 2. FIG. 2 shows a representation of a nucleotide analog of the invention having a linker featuring a carboxyl nitrogen bond between the base and the label, e.g., a dye. The carboxyl nitrogen bond is a cleavable site in the linker. In order to minimize structural perturbation of the base following cleavage, the cleavable site is located close to the base. Initiation and control of cleavage may be by, for example, chemical means (e.g., initiation by adding one or more chemical to alter the pH).


Specifically, referring still to FIG. 2, a nucleotide analog has a linker with a carboxyl nitrogen bond between the base and the label (Step 410). The linker features a cleavable site, a cleavable carboxyl nitrogen bond that when exposed to a pH of about 11.8 (Step 420) cleaves and removes the label and a portion of the linker. Specifically, upon exposure to a pH of about 11.8 the carboxyl, a portion of the linker, and the label are separated from a nitrogen that is attached to the base. The cleaved nitrogen bond bonds with a Hydrogen (e.g., a Hydrogen available in the solution having a pH of 11.8) and remains with the base (Step 430). Optionally, the linker remaining attached to the base may be reactive and can optionally be capped, rendering it unreactive.


Detection


Any detection method may be used to identify an incorporated nucleotide analog that is suitable for the type of label employed. Thus, exemplary detection methods include radioactive detection, optical absorbance detection, e.g., UV-visible absorbance detection, optical emission detection, e.g., fluorescence or chemiluminescence. Single-molecule fluorescence can be made using a conventional microscope equipped with total internal reflection (TIR) illumination. The detectable moiety associated with the extended primers can be detected on a substrate by scanning all or portions of each substrate simultaneously or serially, depending on the scanning method used. For fluorescence labeling, selected regions on a substrate may be serially scanned one-by-one or row-by-row using a fluorescence microscope apparatus, such as described in Fodor (U.S. Pat. No. 5,445,934) and Mathies et al. (U.S. Pat. No. 5,091,652). Devices capable of sensing fluorescence from a single molecule include scanning tunneling microscope (siM) and the atomic force microscope (AFM). Hybridization patterns may also be scanned using a CCD camera (e.g., Model TE/CCD512SF, Princeton Instruments, Trenton, N.J.) with suitable optics (Ploem, in Fluorescent and Luminescent Probes for Biological Activity Mason, T. G. Ed., Academic Press, Landon, pp. 1-11 (1993), such as described in Yershov et al., Proc. Natl. Aca. Sci. 93:4913 (1996), or may be imaged by TV monitoring. For radioactive signals, a phosphorimager device can be used (Johnston et al., Electrophoresis, 13:566, 1990; Drmanac et al., Electrophoresis, 13:566, 1992; 1993). Other commercial suppliers of imaging instruments include General Scanning Inc., (Watertown, Mass. on the World Wide Web at genscan.com), Genix Technologies (Waterloo, Ontario, Canada; on the World Wide Web at confocal.com), and Applied Precision Inc. Such detection methods are particularly useful to achieve simultaneous scanning of multiple attached target nucleic acids.


The present invention provides for detection of molecules from a single nucleotide to a single target nucleic acid molecule. A number of methods are available for this purpose. Methods for visualizing single molecules within nucleic acids labeled with an intercalating dye include, for example, fluorescence microscopy. For example, the fluorescent spectrum and lifetime of a single molecule excited-state can be measured. Standard detectors such as a photomultiplier tube or avalanche photodiode can be used. Full field imaging with a two-stage image intensified COD camera also can be used. Additionally, low noise cooled CCD can also be used to detect single fluorescent molecules.


The detection system for the signal may depend upon the labeling moiety used, which can be defined by the chemistry available. For optical signals, a combination of an optical fiber or charged couple device (CCD) can be used in the detection step. In those circumstances where the substrate is itself transparent to the radiation used, it is possible to have an incident light beam pass through the substrate with the detector located opposite the substrate from the target nucleic acid. For electromagnetic labeling moieties, various forms of spectroscopy systems can be used. Various physical orientations for the detection system are available and discussion of important design parameters is provided in the art.


A number of approaches can be used to detect incorporation of fluorescently-labeled nucleotides into a single nucleic acid molecule. Optical setups include near-field scanning microscopy, far-field confocal microscopy, wide-field epi-illumination, light scattering, dark field microscopy, photoconversion, single and/or multiphoton excitation, spectral wavelength discrimination, fluorophore identification, evanescent wave illumination, and total internal reflection fluorescence (TIRF) microscopy. In general, certain methods involve detection of laser-activated fluorescence using a microscope equipped with a camera. Suitable photon detection systems include, but are not limited to, photodiodes and intensified CCD cameras. For example, an intensified charge couple device (ICCD) camera can be used. The use of an ICCD camera to image individual fluorescent dye molecules in a fluid near a surface provides numerous advantages. For example, with an ICCD optical setup, it is possible to acquire a sequence of images (movies) of fluorophores.


Some embodiments of the present invention use TIRF microscopy for two-dimensional imaging. TIRF microscopy uses totally internally reflected excitation light and is well known in the art. See, e.g., the World Wide Web at nikon-instruments.jp/eng/page/products/tirf.aspx. In certain embodiments, detection is carried out using evanescent wave illumination and total internal reflection fluorescence microscopy. An evanescent light field can be set up at the surface, for example, to image fluorescently-labeled nucleic acid molecules. When a laser beam is totally reflected at the interface between a liquid and a solid substrate (e.g., a glass), the excitation light beam penetrates only a short distance into the liquid. The optical field does not end abruptly at the reflective interface, but its intensity falls off exponentially with distance. This surface electromagnetic field, called the “evanescent wave,” can selectively excite fluorescent molecules in the liquid near the interface. The thin evanescent optical field at the interface provides low background and facilitates the detection of single molecules with high signal-to-noise ratio at visible wavelengths.


The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting on the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

Claims
  • 1. A nucleotide analog having the structure:
  • 2. The nucleotide analog of claim 1, wherein said label is an optically-detectable label.
  • 3. The nucleotide analog of claim 2, wherein said optically-detectable label is a fluorescent label.
  • 4. The nucleotide analog of claim 1, wherein B is selected from the group consisting of cytosine, uracil, thymine, adenine, guanine, and analogs thereof.
  • 5. The nucleotide analog of claim 1, wherein said linker comprises a cleavable bond.
  • 6. The nucleotide analog of claim 5, wherein said cleavable bond is a chemically cleavable bond.
  • 7. The nucleotide analog of claim 5, wherein said cleavable bond is a photochemically cleavable bond.
  • 8. The nucleotide analog of claim 5, wherein said cleavable bond is cleaved upon exposure to a pH from about 11.3 to about 12.3.
  • 9. The nucleotide analog of claim 5, wherein said cleavable bond is cleaved upon exposure to a pH of about 11.8.
  • 10. A nucleotide analog having the structure:
  • 11. The nucleotide analog of claim 10, wherein said label is an optically-detectable label.
  • 12. The nucleotide analog of claim 11, wherein said optically-detectable label is a fluorescent label.
US Referenced Citations (435)
Number Name Date Kind
3996345 Ullman et al. Dec 1976 A
4119368 Yamazaki Oct 1978 A
4153855 Feingold May 1979 A
4344064 Bitler et al. Aug 1982 A
4351760 Khanna et al. Sep 1982 A
4683195 Mullis et al. Jul 1987 A
4683202 Mullis Jul 1987 A
4707237 Lepp et al. Nov 1987 A
4711955 Ward et al. Dec 1987 A
4725677 Kosler et al. Feb 1988 A
4739044 Stabinskv Apr 1988 A
4757141 Fung et al. Jul 1988 A
4793705 Shera Dec 1988 A
4811218 Hunkapiller et al. Mar 1989 A
4863849 Melamede Sep 1989 A
4865968 Orgel et al. Sep 1989 A
4889818 Gelfand et al. Dec 1989 A
4942124 Church Jul 1990 A
4962037 Jett et al. Oct 1990 A
4971903 Hyman Nov 1990 A
4979824 Mathies et al. Dec 1990 A
4994368 Goodman et al. Feb 1991 A
4994372 Tabor et al. Feb 1991 A
4994373 Stavrianopoulos et al. Feb 1991 A
5085562 Van Lintel Feb 1992 A
5091652 Mathies et al. Feb 1992 A
5096388 Weinberg Mar 1992 A
5096554 Chin et al. Mar 1992 A
5108892 Burke et al. Apr 1992 A
5112736 Caldwell et al. May 1992 A
RE34069 Koster et al. Sep 1992 E
5143854 Pirrung et al. Sep 1992 A
5167784 Noolandi Dec 1992 A
5171132 Miyazaki et al. Dec 1992 A
5198540 Koster Mar 1993 A
5209834 Shera May 1993 A
5224843 Van Lintel Jul 1993 A
5242796 Prober et al. Sep 1993 A
5242797 Hirschfeld Sep 1993 A
5258506 Urdea et al. Nov 1993 A
5259737 Kamisuki et al. Nov 1993 A
5260433 Engelhardt et al. Nov 1993 A
5265327 Faris et al. Nov 1993 A
5267152 Yang et al. Nov 1993 A
5302509 Cheeseman Apr 1994 A
5304487 Wilding et al. Apr 1994 A
5306403 Vo-Dinh Apr 1994 A
5336062 Richter Aug 1994 A
5360523 Middendorf et al. Nov 1994 A
5375979 Trah Dec 1994 A
5376252 Ekstrom et al. Dec 1994 A
5403709 Agrawal et al. Apr 1995 A
5405747 Ieu et al. Apr 1995 A
5405783 Pirrung et al. Apr 1995 A
5409811 Tabor et al. Apr 1995 A
5424186 Fodor et al. Jun 1995 A
5436149 Barnes Jul 1995 A
5449767 Ward et al. Sep 1995 A
5476928 Ward et al. Dec 1995 A
5484701 Cocuzza et al. Jan 1996 A
5492806 Drmanac et al. Feb 1996 A
5514256 Douthart et al. May 1996 A
5518900 Nikiforov et al. May 1996 A
5525464 Drmanac et al. Jun 1996 A
5529465 Zengerle et al. Jun 1996 A
5534125 Middendorf et al. Jul 1996 A
5547839 Dower et al. Aug 1996 A
5547859 Goodman et al. Aug 1996 A
5556790 Pettit Sep 1996 A
5558991 Trainor Sep 1996 A
5599695 Pease et al. Feb 1997 A
5610287 Nikiforov et al. Mar 1997 A
5631734 Stern et al. May 1997 A
5632957 Heller et al. May 1997 A
5654149 Mendoza et al. Aug 1997 A
5659171 Young et al. Aug 1997 A
5670346 Reeve et al. Sep 1997 A
5674716 Tabor et al. Oct 1997 A
5675155 Pentoney, Jr. et al. Oct 1997 A
5688648 Mathies et al. Nov 1997 A
5695940 Drmanac et al. Dec 1997 A
5705018 Hartley Jan 1998 A
5707506 Douthart et al. Jan 1998 A
5710628 Waterhouse et al. Jan 1998 A
5712476 Renfrew et al. Jan 1998 A
5733729 Lipshutz et al. Mar 1998 A
5741640 Fuller Apr 1998 A
5741644 Kambara et al. Apr 1998 A
5744305 Fodor et al. Apr 1998 A
5744312 Mamone et al. Apr 1998 A
5750341 Macevicz et al. May 1998 A
5753788 Fodor et al. May 1998 A
5755943 Middendorf et al. May 1998 A
5756285 Fuller May 1998 A
5759014 Van Lintel Jun 1998 A
5759374 Takahashi et al. Jun 1998 A
5762876 Lincoln et al. Jun 1998 A
5763594 Hiatt et al. Jun 1998 A
5776767 Stevens et al. Jul 1998 A
5776782 Tsuji Jul 1998 A
5789168 Leushner et al. Aug 1998 A
5795722 Lacroix et al. Aug 1998 A
5795782 Church et al. Aug 1998 A
5807679 Kamb Sep 1998 A
5808045 Hiatt et al. Sep 1998 A
5830657 Leushner et al. Nov 1998 A
5831070 Pease et al. Nov 1998 A
5832165 Reichert et al. Nov 1998 A
5834758 Trulson et al. Nov 1998 A
5836750 Cabuz Nov 1998 A
5837832 Chee et al. Nov 1998 A
5837860 Anderson et al. Nov 1998 A
5846396 Zanzucchi et al. Dec 1998 A
5846727 Soper et al. Dec 1998 A
5853979 Green et al. Dec 1998 A
5858671 Jones Jan 1999 A
5861287 Metzker et al. Jan 1999 A
5863722 Brenner Jan 1999 A
5872244 Hiatt et al. Feb 1999 A
5876187 Afromowitz Mar 1999 A
5876934 Duthie et al. Mar 1999 A
5882904 Riedl et al. Mar 1999 A
5885813 Davis et al. Mar 1999 A
5889165 Fodor et al. Mar 1999 A
5902723 Dower et al. May 1999 A
5908755 Kumar et al. Jun 1999 A
5916747 Gilchrist et al. Jun 1999 A
5922591 Anderson et al. Jul 1999 A
5922608 Farnsworth et al. Jul 1999 A
5928906 Koster et al. Jul 1999 A
5928919 Reha-Krantz et al. Jul 1999 A
5945283 Kwok et al. Aug 1999 A
5945284 Livak et al. Aug 1999 A
5945312 Goodman et al. Aug 1999 A
5945325 Arnold et al. Aug 1999 A
5948614 Chatterjee Sep 1999 A
5952174 Nikiforov et al. Sep 1999 A
5954932 Takahashi et al. Sep 1999 A
5958703 Dower et al. Sep 1999 A
5959781 Kintz et al. Sep 1999 A
5959837 Yu Sep 1999 A
5965446 Ishikawa Oct 1999 A
5968740 Fodor et al. Oct 1999 A
5974164 Chee Oct 1999 A
5976338 Fujita et al. Nov 1999 A
5981186 Gabe et al. Nov 1999 A
5981956 Stern Nov 1999 A
5994058 Senapathy Nov 1999 A
5994085 Cantor Nov 1999 A
6002471 Quake Dec 1999 A
6005663 Waterhouse et al. Dec 1999 A
6007309 Hartley Dec 1999 A
6015714 Baldarelli et al. Jan 2000 A
6017702 Lee et al. Jan 2000 A
6018041 Drmanac et al. Jan 2000 A
6020457 Klimash et al. Feb 2000 A
6024925 Little et al. Feb 2000 A
6025136 Drmanac Feb 2000 A
6028190 Mathies et al. Feb 2000 A
6030782 Anderson et al. Feb 2000 A
6043080 Lipshutz et al. Mar 2000 A
6046005 Ju et al. Apr 2000 A
6049380 Goodwin et al. Apr 2000 A
6051380 Sosnowski et al. Apr 2000 A
6066454 Lipshutz et al. May 2000 A
6071394 Cheng et al. Jun 2000 A
6077664 Slater et al. Jun 2000 A
6077674 Schleifer et al. Jun 2000 A
6087095 Rosenthal et al. Jul 2000 A
6087099 Gupte et al. Jul 2000 A
6094274 Yokoi Jul 2000 A
6107032 Kilger et al. Aug 2000 A
6107044 Nikiforov Aug 2000 A
6107061 Johnson Aug 2000 A
6132580 Mathies et al. Oct 2000 A
6133436 Koster et al. Oct 2000 A
6136212 Mastrangelo et al. Oct 2000 A
6136962 Shi et al. Oct 2000 A
6140053 Koster Oct 2000 A
6140494 Hamilton et al. Oct 2000 A
6141096 Stern et al. Oct 2000 A
6143151 Middendorf et al. Nov 2000 A
6147205 McGall et al. Nov 2000 A
6156501 McGall et al. Dec 2000 A
6165694 Liu Dec 2000 A
6177249 Kwok et al. Jan 2001 B1
6197506 Fodor et al. Mar 2001 B1
6197595 Anderson et al. Mar 2001 B1
6207381 Larsson et al. Mar 2001 B1
6207960 Stern Mar 2001 B1
6210896 Chan Apr 2001 B1
6214246 Craighead Apr 2001 B1
6214987 Hiatt et al. Apr 2001 B1
6221592 Schwartz et al. Apr 2001 B1
6221654 Quake et al. Apr 2001 B1
6225052 Batz et al. May 2001 B1
6225062 Dunn et al. May 2001 B1
6225092 Kilger et al. May 2001 B1
6225109 Juncosa et al. May 2001 B1
6225567 Kester May 2001 B1
6225625 Pirrung et al. May 2001 B1
6228593 Lipshutz et al. May 2001 B1
6232075 Williams May 2001 B1
6232103 Short May 2001 B1
6235465 Kolberg et al. May 2001 B1
6235473 Friedman et al. May 2001 B1
6242180 Chee Jun 2001 B1
6242528 Clark et al. Jun 2001 B1
6245506 Laugharn, Jr. et al. Jun 2001 B1
6245507 Bogdanov Jun 2001 B1
6245518 Baier Jun 2001 B1
6251610 Gupte et al. Jun 2001 B1
6255083 Williams Jul 2001 B1
6255475 Kwiatkowski Jul 2001 B1
6258533 Jones Jul 2001 B1
6261775 Bastian et al. Jul 2001 B1
6261776 Pirrung et al. Jul 2001 B1
6261848 Anderson et al. Jul 2001 B1
6262838 Montagu Jul 2001 B1
6263286 Gilmanshin et al. Jul 2001 B1
6268152 Fodor et al. Jul 2001 B1
6268219 Mcbride et al. Jul 2001 B1
6269846 Overbeck et al. Aug 2001 B1
6270644 Mathies et al. Aug 2001 B1
6270961 Drmanac Aug 2001 B1
6274320 Rothberg et al. Aug 2001 B1
6274351 Peponnet Aug 2001 B1
6277604 Peponnet Aug 2001 B1
6280954 Ulfendahl Aug 2001 B1
6284460 Fodor et al. Sep 2001 B1
6287821 Shi et al. Sep 2001 B1
6294336 Boyce-Jacino et al. Sep 2001 B1
6294337 Hayashizaki Sep 2001 B1
6306607 Williams Oct 2001 B2
6309601 Juncosa et al. Oct 2001 B1
6309701 Barbera-Guillem Oct 2001 B1
6309824 Drmanac Oct 2001 B1
6309836 Kwiatowski Oct 2001 B1
6309886 Ambrose et al. Oct 2001 B1
6310189 Fodor et al. Oct 2001 B1
6312893 Van Ness et al. Nov 2001 B1
6316191 Drmanac et al. Nov 2001 B1
6322968 Head et al. Nov 2001 B1
6331439 Cherukuri et al. Dec 2001 B1
6333183 Evans et al. Dec 2001 B1
6335824 Overbeck Jan 2002 B1
6337185 Asp et al. Jan 2002 B1
6337188 Head et al. Jan 2002 B1
6342326 Milton Jan 2002 B1
6344325 Quake et al. Feb 2002 B1
6346379 Gelfand et al. Feb 2002 B1
6346413 Fodor et al. Feb 2002 B1
6355420 Chao Mar 2002 B1
6355432 Fodor et al. Mar 2002 B1
6361671 Mathies et al. Mar 2002 B1
6361937 Stryer Mar 2002 B1
6368562 Yao Apr 2002 B1
6368699 Gilbert et al. Apr 2002 B1
6383749 Bochkariov et al. May 2002 B2
6387626 Shi et al. May 2002 B1
6395232 McBride May 2002 B1
6395559 Swenson May 2002 B1
6397150 Izmailov May 2002 B1
6399364 Reeve et al. Jun 2002 B1
6401267 Drmanac Jun 2002 B1
6403311 Chao Jun 2002 B1
6403315 Drmanac Jun 2002 B1
6403317 Anderson Jun 2002 B1
6403320 Read et al. Jun 2002 B1
6403957 Fodor et al. Jun 2002 B1
6404907 Gilchrist et al. Jun 2002 B1
6406893 Knapp et al. Jun 2002 B1
6407858 Montagu Jun 2002 B1
6408878 Unger et al. Jun 2002 B2
6416952 Pirrung et al. Jul 2002 B1
6420169 Read et al. Jul 2002 B1
6423273 O'Mara Jul 2002 B1
6432634 Digby et al. Aug 2002 B1
6436641 Izmailov Aug 2002 B1
6436646 Nikiforov Aug 2002 B1
6440664 Digby et al. Aug 2002 B1
6440722 Knapp et al. Aug 2002 B1
6444106 Mcbride et al. Sep 2002 B1
6444173 Sjursen et al. Sep 2002 B1
6444424 Chatterjee et al. Sep 2002 B1
6444461 Knapp et al. Sep 2002 B1
6447724 Jensen et al. Sep 2002 B1
6448090 McBride Sep 2002 B1
6451536 Fodor et al. Sep 2002 B1
6479267 Davis et al. Nov 2002 B1
6485690 Pfost et al. Nov 2002 B1
6485909 Hong et al. Nov 2002 B1
6485944 Church et al. Nov 2002 B1
6495363 Bogdanov Dec 2002 B2
6506560 Hughes et al. Jan 2003 B1
6511803 Church et al. Jan 2003 B1
6514706 Von Kalle et al. Feb 2003 B1
6521428 Senapathy Feb 2003 B1
6524829 Seeger Feb 2003 B1
6528258 Russell Mar 2003 B1
6528288 Senapathy Mar 2003 B2
6537755 Drmanac Mar 2003 B1
6537757 Langmore et al. Mar 2003 B1
6546340 Lipshutz et al. Apr 2003 B2
6551784 Fodor et al. Apr 2003 B2
6551817 Besemer et al. Apr 2003 B2
6554987 Gilchrist et al. Apr 2003 B1
6555349 O'Donnell Apr 2003 B1
6558945 Kao May 2003 B1
6562566 Hoheisel May 2003 B1
6566059 Stanton, Jr. et al. May 2003 B1
6566515 McGall et al. May 2003 B1
6573047 Hung et al. Jun 2003 B1
6573374 Muehleger et al. Jun 2003 B1
6576424 Fodor et al. Jun 2003 B2
6576425 McGall et al. Jun 2003 B2
6579704 Short Jun 2003 B2
6582923 Stanton, Jr. et al. Jun 2003 B2
6585939 Dapprich Jul 2003 B1
6607888 Schwartz et al. Aug 2003 B2
6610482 Fodor et al. Aug 2003 B1
6613513 Kopf-Sill et al. Sep 2003 B1
6623928 Van Ness et al. Sep 2003 B2
6627748 Ju et al. Sep 2003 B1
6632655 Mehta et al. Oct 2003 B1
6642001 Bolk et al. Nov 2003 B1
6664079 Ju et al. Dec 2003 B2
6719868 Schueller et al. Apr 2004 B1
6750018 Kambara et al. Jun 2004 B2
6762048 Williams Jul 2004 B2
6780591 Williams et al. Aug 2004 B2
6783938 Nygren et al. Aug 2004 B2
6787308 Balasubramanian et al. Sep 2004 B2
6818395 Quake et al. Nov 2004 B1
6908736 Densham Jun 2005 B1
6911345 Quake et al. Jun 2005 B2
7057026 Barnes et al. Jun 2006 B2
20010024790 Kambara et al. Sep 2001 A1
20010044531 McGall et al. Nov 2001 A1
20010046681 Senapathy Nov 2001 A1
20020009744 Bogdanov Jan 2002 A1
20020012910 Weiss et al. Jan 2002 A1
20020015961 Kwiatkowski Feb 2002 A1
20020025529 Quake et al. Feb 2002 A1
20020032320 Burgess et al. Mar 2002 A1
20020034792 Kilger et al. Mar 2002 A1
20020039738 Williams et al. Apr 2002 A1
20020042112 Koster et al. Apr 2002 A1
20020045182 Singh et al. Apr 2002 A1
20020051992 Bridgham et al. May 2002 A1
20020053532 Quake et al. May 2002 A1
20020061529 Bridgham et al. May 2002 A1
20020072055 Jones Jun 2002 A1
20020086318 Manalis et al. Jul 2002 A1
20020102586 Ju et al. Aug 2002 A1
20020102595 Davis Aug 2002 A1
20020106673 Drmanac et al. Aug 2002 A1
20020115076 Williams Aug 2002 A1
20020115092 Rebek, Jr. Aug 2002 A1
20020119484 Weidenhammer et al. Aug 2002 A1
20020123046 Smith et al. Sep 2002 A1
20020137046 Koster Sep 2002 A1
20020137052 Bridgham et al. Sep 2002 A1
20020137062 Williams et al. Sep 2002 A1
20020138205 Miller et al. Sep 2002 A1
20020142329 Matray et al. Oct 2002 A1
20020142333 Gelfand et al. Oct 2002 A1
20020146704 Head et al. Oct 2002 A1
20020146726 Matray et al. Oct 2002 A1
20020150903 Koster Oct 2002 A1
20020150938 Kneipp et al. Oct 2002 A1
20020164629 Quake et al. Nov 2002 A1
20020168642 Drukier Nov 2002 A1
20020168678 Williams et al. Nov 2002 A1
20020172948 Perlin Nov 2002 A1
20020177129 Paabo et al. Nov 2002 A1
20020182601 Sampson et al. Dec 2002 A1
20020192661 Paabo et al. Dec 2002 A1
20020192662 Boyce-Jacino et al. Dec 2002 A1
20020192691 Drmanac Dec 2002 A1
20020197618 Sampson Dec 2002 A1
20030003272 Laguitton Jan 2003 A1
20030003498 Digby et al. Jan 2003 A1
20030008285 Fischer Jan 2003 A1
20030008413 Kim et al. Jan 2003 A1
20030017461 Singh et al. Jan 2003 A1
20030022207 Balasubramanian et al. Jan 2003 A1
20030027140 Ju et al. Feb 2003 A1
20030036080 Jensen et al. Feb 2003 A1
20030044778 Goelet et al. Mar 2003 A1
20030044779 Goelet et al. Mar 2003 A1
20030044781 Korlach et al. Mar 2003 A1
20030044816 Denison et al. Mar 2003 A1
20030054181 Swerdlow et al. Mar 2003 A1
20030054361 Heller Mar 2003 A1
20030058440 Scott et al. Mar 2003 A1
20030058799 Yamakawa et al. Mar 2003 A1
20030059778 Berlin et al. Mar 2003 A1
20030060431 Simmonds et al. Mar 2003 A1
20030064366 Hardin et al. Apr 2003 A1
20030064398 Barnes Apr 2003 A1
20030064483 Shaw et al. Apr 2003 A1
20030087237 Hong et al. May 2003 A1
20030087300 Knapp et al. May 2003 A1
20030092005 Levene et al. May 2003 A1
20030092007 Gibbs et al. May 2003 A1
20030096258 Fu et al. May 2003 A1
20030100006 Senapathy May 2003 A1
20030104437 Barnes et al. Jun 2003 A1
20030104466 Knapp et al. Jun 2003 A1
20030108867 Chee et al. Jun 2003 A1
20030138809 Williams et al. Jul 2003 A1
20030148344 Rothberg et al. Aug 2003 A1
20030162213 Fuller et al. Aug 2003 A1
20030186227 Balasubramanian et al. Oct 2003 A1
20030186255 Williams et al. Oct 2003 A1
20030190627 Zhao et al. Oct 2003 A1
20030190647 Odera Oct 2003 A1
20030190663 Yang et al. Oct 2003 A1
20030194722 Odedra et al. Oct 2003 A1
20030194740 Williams Oct 2003 A1
20030215862 Wallace et al. Nov 2003 A1
20040009487 Kadushin et al. Jan 2004 A1
20040014096 Anderson et al. Jan 2004 A1
20040029115 Dower et al. Feb 2004 A9
20040038206 Zhang et al. Feb 2004 A1
20040054162 Hanna Mar 2004 A1
20040106110 Balasubramanian et al. Jun 2004 A1
20040110162 Lapidus et al. Jun 2004 A1
20040126770 Kumar et al. Jul 2004 A1
20050014175 Quake et al. Jan 2005 A1
20050100932 Lapidus et al. May 2005 A1
20050147992 Quake et al. Jul 2005 A1
20050170367 Quake et al. Aug 2005 A1
20050239085 Buzby et al. Oct 2005 A1
Foreign Referenced Citations (175)
Number Date Country
10256898 Sep 2004 DE
0223618 May 1987 EP
0412883 Feb 1991 EP
0579997 Jan 1994 EP
0703364 Mar 1996 EP
0706004 Apr 1996 EP
0779436 Jun 1997 EP
0845603 Jun 1998 EP
0932700 Aug 1999 EP
0946752 Oct 1999 EP
0955085 Nov 1999 EP
0999055 May 2000 EP
0706004 Aug 2003 EP
2155152 Sep 1985 GB
2308460 Jun 1997 GB
2400518 Oct 2004 GB
63-241356 Oct 1988 JP
9500589 Feb 1995 SE
8903432 Apr 1989 WO
8909283 Oct 1989 WO
9013666 Nov 1990 WO
9015070 Dec 1990 WO
9106678 May 1991 WO
9210092 Jun 1992 WO
9210587 Jun 1992 WO
9305183 Mar 1993 WO
9306121 Apr 1993 WO
9321340 Oct 1993 WO
9512608 May 1995 WO
9527080 Oct 1995 WO
9604547 Feb 1996 WO
9612014 Apr 1996 WO
9612039 Apr 1996 WO
9627025 Sep 1996 WO
9702488 Jan 1997 WO
9722076 Jun 1997 WO
9723650 Jun 1997 WO
9737041 Oct 1997 WO
9739150 Oct 1997 WO
9740184 Oct 1997 WO
9741258 Nov 1997 WO
9741259 Nov 1997 WO
9742348 Nov 1997 WO
9800708 Jan 1998 WO
9802575 Jan 1998 WO
9803684 Jan 1998 WO
9807069 Feb 1998 WO
9813523 Apr 1998 WO
9808978 May 1998 WO
9820019 May 1998 WO
9820020 May 1998 WO
9820166 May 1998 WO
9821361 May 1998 WO
9827228 Jun 1998 WO
9828440 Jul 1998 WO
9833939 Aug 1998 WO
9840520 Sep 1998 WO
9841650 Sep 1998 WO
9841657 Sep 1998 WO
9844152 Oct 1998 WO
9845481 Oct 1998 WO
9853300 Nov 1998 WO
9854669 Dec 1998 WO
9855593 Dec 1998 WO
9901768 Jan 1999 WO
9905221 Feb 1999 WO
9905315 Feb 1999 WO
9906422 Feb 1999 WO
9913109 Mar 1999 WO
9913110 Mar 1999 WO
9909616 Apr 1999 WO
9917093 Apr 1999 WO
9919516 Apr 1999 WO
9924797 May 1999 WO
9927137 Jun 1999 WO
9931278 Jun 1999 WO
9937810 Jul 1999 WO
9939001 Aug 1999 WO
9940105 Aug 1999 WO
9940223 Aug 1999 WO
9941410 Aug 1999 WO
0030591 Sep 1999 WO
9944045 Sep 1999 WO
9945153 Sep 1999 WO
9947539 Sep 1999 WO
9947706 Sep 1999 WO
9953423 Oct 1999 WO
9957321 Nov 1999 WO
9961888 Dec 1999 WO
9964437 Dec 1999 WO
9964840 Dec 1999 WO
9965938 Dec 1999 WO
9966076 Dec 1999 WO
9966313 Dec 1999 WO
0000637 Jan 2000 WO
0006770 Feb 2000 WO
0009753 Feb 2000 WO
0011223 Mar 2000 WO
0017397 Mar 2000 WO
0026935 May 2000 WO
0034523 Jun 2000 WO
0037680 Jun 2000 WO
0040750 Jul 2000 WO
0040758 Jul 2000 WO
0042223 Jul 2000 WO
0043540 Jul 2000 WO
0043752 Jul 2000 WO
0050642 Aug 2000 WO
0053805 Sep 2000 WO
0053812 Sep 2000 WO
0056937 Sep 2000 WO
0058507 Oct 2000 WO
0058516 Oct 2000 WO
0068410 Nov 2000 WO
0070073 Nov 2000 WO
0071755 Nov 2000 WO
0079007 Dec 2000 WO
01001025 Jan 2001 WO
0116375 Mar 2001 WO
0123610 Apr 2001 WO
0124937 Apr 2001 WO
0125480 Apr 2001 WO
0131055 May 2001 WO
0132930 May 2001 WO
0138574 May 2001 WO
0148184 May 2001 WO
0142496 Jun 2001 WO
0157248 Aug 2001 WO
0157249 Aug 2001 WO
0161044 Aug 2001 WO
0164838 Sep 2001 WO
0175154 Oct 2001 WO
0179536 Oct 2001 WO
0185991 Nov 2001 WO
0192284 Dec 2001 WO
0196607 Dec 2001 WO
0200343 Jan 2002 WO
0202584 Jan 2002 WO
0202795 Jan 2002 WO
0202813 Jan 2002 WO
0203305 Jan 2002 WO
0204680 Jan 2002 WO
0220836 Mar 2002 WO
0220837 Mar 2002 WO
0227032 Apr 2002 WO
0229106 Apr 2002 WO
02030486 Apr 2002 WO
0235441 May 2002 WO
0236832 May 2002 WO
0244414 Jun 2002 WO
02061126 Aug 2002 WO
02061127 Aug 2002 WO
02072779 Sep 2002 WO
02072892 Sep 2002 WO
02077694 Oct 2002 WO
02079519 Oct 2002 WO
02088381 Nov 2002 WO
02088382 Nov 2002 WO
02097113 Dec 2002 WO
02099398 Dec 2002 WO
03002767 Jan 2003 WO
03016565 Feb 2003 WO
03020895 Mar 2003 WO
03020968 Mar 2003 WO
03021010 Mar 2003 WO
03031947 Apr 2003 WO
03044678 May 2003 WO
03048178 Jun 2003 WO
03048991 Jun 2003 WO
03062897 Jul 2003 WO
03106642 Dec 2003 WO
2004061119 Jul 2004 WO
2004074503 Sep 2004 WO
2005047523 May 2005 WO
2005080605 Sep 2005 WO
Related Publications (1)
Number Date Country
20070128614 A1 Jun 2007 US